PDF(Pubmed)
Abstract：
UNASSIGNED: The Eastern Mediterranean Regional Office (EMRO) region accounts for almost 8% of all global Mycobacterium tuberculosis (TB) cases, with TB incidence rates ranging from 1 per 100,000 per year in the United Arab Emirates (UAE) to 204 per 100,000 in Djibouti. The national surveillance data from the Middle East and North Africa (MENA) region on the epidemiology and antimicrobial resistance trends of TB, including MDR-TB remains scarce.
UNASSIGNED: A retrospective 12-year analysis of N = 8,086 non-duplicate diagnostic Mycobacterium tuberculosis complex (MTB complex) isolates from the UAE was conducted. Data were generated through routine patient care during the 2010-2021 years, collected by trained personnel and reported by participating surveillance sites to the UAE National Antimicrobial Resistance (AMR) Surveillance program. Data analysis was conducted with WHONET, a windows-based microbiology laboratory database management software developed by the World Health Organization Collaborating Center for Surveillance of Antimicrobial Resistance, Boston, United States (https://whonet.org/).
UNASSIGNED: A total of 8,086 MTB-complex isolates were analyzed. MTB-complex was primarily isolated from respiratory samples (sputum 80.1%, broncho-alveolar lavage 4.6%, pleural fluid 4.1%). Inpatients accounted for 63.2%, including 1.3% from ICU. Nationality was known for 84.3% of patients, including 3.8% Emiratis. Of UAE non-nationals, 80.5% were from 110 countries, most of which were Asian countries. India accounted for 20.8%, Pakistan 13.6%, Philippines 12.7%, and Bangladesh 7.8%. Rifampicin-resistant MTB-complex isolates (RR-TB) were found in 2.8% of the isolates, resistance to isoniazid, streptomycin, pyrazinamide, and ethambutol, was 8.9, 6.9, 3.4 and 0.4%, respectively. A slightly increasing trend of resistance among MTB-complex was observed for rifampicin from 2.5% (2010) to 2.8% (2021).
UNASSIGNED: Infections due to MTB-complex are relatively uncommon in the United Arab Emirates compared to other countries in the MENA region. Most TB patients in the UAE are of Asian origin, mainly from countries with a high prevalence of TB. Resistance to first line anti-tuberculous drugs is generally low, however increasing trends for MDR-TB mainly rifampicin linked resistance is a major concern. MDR-TB was not associated with a higher mortality, admission to ICU, or increased length of hospitalization as compared to non-MDR-TB.
UNASSIGNED: A retrospective 12-year analysis of N = 8,086 non-duplicate diagnostic Mycobacterium tuberculosis complex (MTB complex) isolates from the UAE was conducted. Data were generated through routine patient care during the 2010-2021 years, collected by trained personnel and reported by participating surveillance sites to the UAE National Antimicrobial Resistance (AMR) Surveillance program. Data analysis was conducted with WHONET, a windows-based microbiology laboratory database management software developed by the World Health Organization Collaborating Center for Surveillance of Antimicrobial Resistance, Boston, United States (https://whonet.org/).
UNASSIGNED: A total of 8,086 MTB-complex isolates were analyzed. MTB-complex was primarily isolated from respiratory samples (sputum 80.1%, broncho-alveolar lavage 4.6%, pleural fluid 4.1%). Inpatients accounted for 63.2%, including 1.3% from ICU. Nationality was known for 84.3% of patients, including 3.8% Emiratis. Of UAE non-nationals, 80.5% were from 110 countries, most of which were Asian countries. India accounted for 20.8%, Pakistan 13.6%, Philippines 12.7%, and Bangladesh 7.8%. Rifampicin-resistant MTB-complex isolates (RR-TB) were found in 2.8% of the isolates, resistance to isoniazid, streptomycin, pyrazinamide, and ethambutol, was 8.9, 6.9, 3.4 and 0.4%, respectively. A slightly increasing trend of resistance among MTB-complex was observed for rifampicin from 2.5% (2010) to 2.8% (2021).
UNASSIGNED: Infections due to MTB-complex are relatively uncommon in the United Arab Emirates compared to other countries in the MENA region. Most TB patients in the UAE are of Asian origin, mainly from countries with a high prevalence of TB. Resistance to first line anti-tuberculous drugs is generally low, however increasing trends for MDR-TB mainly rifampicin linked resistance is a major concern. MDR-TB was not associated with a higher mortality, admission to ICU, or increased length of hospitalization as compared to non-MDR-TB.
摘要：
东地中海区域办事处（EMRO）地区占全球所有结核分枝杆菌（TB）病例的近8％，结核病发病率从阿拉伯联合酋长国(UAE)的每年每100,000人中有1人到吉布提的每100,000人中有204人不等。中东和北非（MENA）地区关于结核病流行病学和抗菌素耐药性趋势的国家监测数据，包括耐多药结核病仍然很少。
■对来自阿联酋的N=8,086个非重复诊断结核分枝杆菌复合体（MTB复合体）分离株进行了12年的回顾性分析。数据是通过2010-2021年的常规患者护理产生的，由训练有素的人员收集，并由参与监测点向阿联酋国家抗菌素耐药性（AMR）监测计划报告。使用WHONET进行数据分析，由世界卫生组织抗菌素耐药性监测合作中心开发的基于windows的微生物实验室数据库管理软件，波士顿,美国(https://whonet.org/)。
■分析了总共8,086个MTB复合物分离株。MTB复合物主要从呼吸道样本中分离（痰液80.1％，支气管肺泡灌洗4.6%，胸腔积液4.1%)。住院患者占63.2%,包括来自ICU的1.3%。84.3%的患者知道国籍，包括3.8%的阿联酋人。在阿联酋非国民中，80.5%来自110个国家，其中大部分是亚洲国家。印度占20.8%,巴基斯坦13.6%,菲律宾12.7%,孟加拉国7.8%。在2.8％的分离株中发现了利福平耐药的MTB复合物分离株（RR-TB），对异烟肼的抗性，链霉素,吡嗪酰胺,还有乙胺丁醇,分别为8.9、6.9、3.4和0.4%，分别。观察到利福平的MTB复合物中的抗性从2.5％（2010年）略微增加到2.8％（2021年）。
■与中东和北非地区的其他国家相比，在阿拉伯联合酋长国，由MTB复合体引起的感染相对少见。阿联酋的大多数结核病患者来自亚洲，主要来自结核病流行率高的国家。对一线抗结核药物的耐药性普遍较低,然而，主要是利福平相关耐药的耐多药结核病的增加趋势是一个主要问题。耐多药结核病与较高的死亡率无关，入住ICU,与非耐多药结核病相比，住院时间增加。
■对来自阿联酋的N=8,086个非重复诊断结核分枝杆菌复合体（MTB复合体）分离株进行了12年的回顾性分析。数据是通过2010-2021年的常规患者护理产生的，由训练有素的人员收集，并由参与监测点向阿联酋国家抗菌素耐药性（AMR）监测计划报告。使用WHONET进行数据分析，由世界卫生组织抗菌素耐药性监测合作中心开发的基于windows的微生物实验室数据库管理软件，波士顿,美国(https://whonet.org/)。
■分析了总共8,086个MTB复合物分离株。MTB复合物主要从呼吸道样本中分离（痰液80.1％，支气管肺泡灌洗4.6%，胸腔积液4.1%)。住院患者占63.2%,包括来自ICU的1.3%。84.3%的患者知道国籍，包括3.8%的阿联酋人。在阿联酋非国民中，80.5%来自110个国家，其中大部分是亚洲国家。印度占20.8%,巴基斯坦13.6%,菲律宾12.7%,孟加拉国7.8%。在2.8％的分离株中发现了利福平耐药的MTB复合物分离株（RR-TB），对异烟肼的抗性，链霉素,吡嗪酰胺,还有乙胺丁醇,分别为8.9、6.9、3.4和0.4%，分别。观察到利福平的MTB复合物中的抗性从2.5％（2010年）略微增加到2.8％（2021年）。
■与中东和北非地区的其他国家相比，在阿拉伯联合酋长国，由MTB复合体引起的感染相对少见。阿联酋的大多数结核病患者来自亚洲，主要来自结核病流行率高的国家。对一线抗结核药物的耐药性普遍较低,然而，主要是利福平相关耐药的耐多药结核病的增加趋势是一个主要问题。耐多药结核病与较高的死亡率无关，入住ICU,与非耐多药结核病相比，住院时间增加。
